Switch theme
Sign up to access all valuation multiples
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
2011
46
LTM Revenue $0.3M
Last FY EBITDA -$51.7M
-$61.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OnKure Therapeutics has a last 12-month revenue (LTM) of $0.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, OnKure Therapeutics achieved revenue of n/a and an EBITDA of -$51.7M.
OnKure Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OnKure Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$51.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$61.4M | XXX | -$54.4M | XXX | XXX | XXX |
| EBIT Margin | -22275% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$59.3M | XXX | -$52.7M | XXX | XXX | XXX |
| Net Margin | -21490% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, OnKure Therapeutics's stock price is $3.
OnKure Therapeutics has current market cap of $34.2M, and EV of -$61.5M.
See OnKure Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$61.5M | $34.2M | XXX | XXX | XXX | XXX | $-10.93 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, OnKure Therapeutics has market cap of $34.2M and EV of -$61.5M.
OnKure Therapeutics's trades at n/a EV/Revenue multiple, and 1.2x EV/EBITDA.
Equity research analysts estimate OnKure Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OnKure Therapeutics has a P/E ratio of -0.6x.
See valuation multiples for OnKure Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $34.2M | XXX | $34.2M | XXX | XXX | XXX |
| EV (current) | -$61.5M | XXX | -$61.5M | XXX | XXX | XXX |
| EV/Revenue | -223.1x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBIT | 1.0x | XXX | 1.1x | XXX | XXX | XXX |
| EV/Gross Profit | -223.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOnKure Therapeutics's last 12 month revenue growth is 142%
OnKure Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
OnKure Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OnKure Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for OnKure Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 142% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OnKure Therapeutics acquired XXX companies to date.
Last acquisition by OnKure Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . OnKure Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was OnKure Therapeutics founded? | OnKure Therapeutics was founded in 2011. |
| Where is OnKure Therapeutics headquartered? | OnKure Therapeutics is headquartered in United States of America. |
| How many employees does OnKure Therapeutics have? | As of today, OnKure Therapeutics has 46 employees. |
| Who is the CEO of OnKure Therapeutics? | OnKure Therapeutics's CEO is Dr. Nicholas A. Saccomano, PhD. |
| Is OnKure Therapeutics publicy listed? | Yes, OnKure Therapeutics is a public company listed on NAS. |
| What is the stock symbol of OnKure Therapeutics? | OnKure Therapeutics trades under OKUR ticker. |
| When did OnKure Therapeutics go public? | OnKure Therapeutics went public in 2024. |
| Who are competitors of OnKure Therapeutics? | Similar companies to OnKure Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of OnKure Therapeutics? | OnKure Therapeutics's current market cap is $34.2M |
| What is the current revenue of OnKure Therapeutics? | OnKure Therapeutics's last 12 months revenue is $0.3M. |
| What is the current revenue growth of OnKure Therapeutics? | OnKure Therapeutics revenue growth (NTM/LTM) is 142%. |
| What is the current EV/Revenue multiple of OnKure Therapeutics? | Current revenue multiple of OnKure Therapeutics is -223.1x. |
| Is OnKure Therapeutics profitable? | Yes, OnKure Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
